Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zurlo

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
BMC Geriatrics|November 5, 2021
Study protocol: understanding the pathophysiologic mechanisms underlying delirium in older people undergoing hip fracture surgeryR Gamberale, C D'Orlando, S Brunelli, et al.
Oncology|March 3, 2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancerC N Sternberg, P Whelan, J Hetherington, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 22, 2016
Modifiable and non-modifiable risk factors affecting walking recovery after hip fractureG Pioli, F Lauretani, F Pellicciotti, et al.
ESMO Open|September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX studyK Klinghammer, J Fayette, A Kawecki, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
BMC Geriatrics|November 5, 2021
Study protocol: understanding the pathophysiologic mechanisms underlying delirium in older people undergoing hip fracture surgeryR Gamberale, C D'Orlando, S Brunelli, et al.
Oncology|March 3, 2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancerC N Sternberg, P Whelan, J Hetherington, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 22, 2016
Modifiable and non-modifiable risk factors affecting walking recovery after hip fractureG Pioli, F Lauretani, F Pellicciotti, et al.
ESMO Open|September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX studyK Klinghammer, J Fayette, A Kawecki, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
ESMO Open|December 17, 2021
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II studyJ A Ledermann, B Zurawski, F Raspagliesi, et al.
Pageof 5